MedTrace Logo

Imaging CRF X NOP Interactions in Alcohol Use Disorder

NCT07612631 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-29

No results posted yet for this study

Summary

This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.

Conditions

Interventions

DRUG

Hydrocortisone

Intravenous, 1 mg/Kg

RADIATION

Post-hydrocortisone [C-11]NOP-1A PET scan

Radiotracer

RADIATION

Baseline [C-11]NOP-1A PET scan

Radiotracer

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Rajesh Narendran

    lead OTHER

Principal Investigators

  • Rajesh Narendran · University of Pittsburgh

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2031-06-30
Completion
2032-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07612631 on ClinicalTrials.gov